Fred Martin
Disciplined Growth Investors
Fred Martin Novo Nordisk A/S stake
total: 241
Disciplined Growth Investors NVO trades
- Total transactions:
- 3
- New positions:
- 1
- Sold out:
- 1
- Reduced:
- 1
- Held since:
- 2021 Q4
- Held for:
- 2 quarters
- Latest activity:
- 2022 Q2
According to 2026 Q2 report, Fred Martin doesn't hold any Novo Nordisk A/S (NVO) shares. To date, the estimated cost basis is nearly $111.88 for "buy" trades and estimated average "sell" price is $111.19. Disciplined Growth Investors first purchased NVO in 2021 Q4, initially acquiring 3,334 shares. Since the initial investment in Novo Nordisk A/S (NVO), Disciplined Growth Investors has made 2 more transactions.
When did Fred Martin sell Novo Nordisk A/S (NVO)?
Fred Martin sold off the entire Novo Nordisk A/S (NVO) position in 2022 Q2.
When did Fred Martin buy Novo Nordisk A/S (NVO)?
Fred Martin first invested in Novo Nordisk A/S (NVO) in 2021 Q4 at the reported quarter-end price of $111.88 per share.
What's the cost basis of Disciplined Growth Investors's NVO stake?
The estimated cost basis for Novo Nordisk A/S (NVO) stake is around $111.88 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $111.88
- Weighted AVG sell price:
- $111.19
Fred Martin's historical trades in Novo Nordisk A/S
3 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2022 Q2
|
0.00%
|
0
|
$111.19
|
|
-100% (-2,779)
|
-0.01%
|
|
2022 Q1
|
0.01%
|
2,779
|
$111.19
|
$309,000
|
-16.65% (-555)
|
-0%
|
|
2021 Q4
|
0.01%
|
3,334
|
$111.88
|
$373,000
|
new
|
+0.01%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.